<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21055" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Enalapril</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Faruqi</surname>
            <given-names>Arjumand</given-names>
          </name>
          <aff>King George&#x02019;s Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Ashish</given-names>
          </name>
          <aff>Conemaugh Memorial Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arjumand Faruqi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashish Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21055.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Enalapril maleate is a prominent angiotensin-converting enzyme inhibitor&#x000a0;approved by the US Food and Drug Administration (FDA) for the treatment of heart failure, chronic hypertension, and asymptomatic left ventricular dysfunction.&#x000a0;The FDA has approved a fixed-dose combination of enalapril with hydrochlorothiazide. Enalapril is utilized in asymptomatic left ventricular dysfunction as it mitigates progression to symptomatic heart failure and reduces mortality.</p>
        <p>This&#x000a0;activity focuses on various aspects of enalapril, including its indications, mechanism of action, adverse event profile, dosing considerations, monitoring strategies, and potential drug interactions,&#x000a0;specifically emphasizing its crucial role as an effective agent in managing hypertension and associated disorders. This activity also highlights the significance of a collaborative approach involving an interprofessional healthcare team in effectively utilizing and managing enalapril, ensuring shared decision-making and patient safety while delivering optimal care to patients with hypertension and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients who would benefit from enalapril therapy based on indications such as heart failure, chronic hypertension, and asymptomatic left ventricular dysfunction.</p></list-item><list-item><p>Screen patients for potential contraindications and risk factors associated with enalapril therapy, including age-related considerations and drug interactions.</p></list-item><list-item><p>Assess patient response to enalapril therapy by regularly monitoring renal function as well as&#x000a0;blood pressure and electrolyte levels in patients.</p></list-item><list-item><p>Collaborate with interprofessional healthcare teams to coordinate follow-up care and monitoring for patients receiving enalapril therapy, thereby optimizing treatment outcomes and safety.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21055&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21055">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21055.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Enalapril maleate is a prominent&#x000a0;angiotensin-converting enzyme (ACE) inhibitor&#x000a0;approved by the US Food and Drug Administration (FDA) for the treatment of&#x000a0;heart failure,&#x000a0;chronic hypertension, and asymptomatic left ventricular (LV) dysfunction.</p>
        <p>
<bold>FDA Approved Indications</bold>
</p>
        <p>The FDA-approved indications of enalapril are heart failure, chronic hypertension, and&#x000a0;asymptomatic&#x000a0;LV dysfunction, with&#x000a0;ejection fraction (EF) &#x02264;35%.<xref ref-type="bibr" rid="article-21055.r1">[1]</xref><xref ref-type="bibr" rid="article-21055.r2">[2]</xref> As per the American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA) 2022 guideline, ACE inhibitors, such as enalapril, are part of guideline-directed medical therapy. Enalapril is specifically indicated for the treatment of heart failure with reduced EF of &#x0003c;40%.<xref ref-type="bibr" rid="article-21055.r3">[3]</xref></p>
        <p>According to the ACC/AHA clinical practice guideline for hypertension, ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and thiazides are the preferred pharmacotherapy choices.<xref ref-type="bibr" rid="article-21055.r4">[4]</xref> The International Society of Hypertension (ISH) guidelines recommend single-pill combination therapy or fixed-dose combination (FDC) due to increased adherence. The FDA has approved a&#x000a0;FDC of enalapril with hydrochlorothiazide.<xref ref-type="bibr" rid="article-21055.r5">[5]</xref>&#x000a0;Enalapril is utilized in asymptomatic LV dysfunction as it mitigates progression to symptomatic heart failure and reduces mortality.<xref ref-type="bibr" rid="article-21055.r6">[6]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Adults&#x000a0;with ST-elevated myocardial infarction, non-ST&#x02013;elevated acute coronary syndrome, stable coronary artery disease, post-transplant erythrocytosis, and proteinuric chronic kidney disease are candidates for off-label use of enalapril. In addition, enalapril has been found to prevent diabetic nephropathy in normotensive patients.<xref ref-type="bibr" rid="article-21055.r7">[7]</xref>&#x000a0;</p>
        <p>According to the&#x000a0;joint American Diabetes Association (ADA)/Kidney Disease Improving Global Outcomes (KDIGO) guideline, treatment with ACE inhibitors, such as enalapril, is recommended for patients with diabetes and hypertension,&#x000a0;particularly those with an increased urine albumin-to-creatinine ratio (ACR) of 30 to 299 mg/g. Treatment is strongly suggested for those with a urinary ACR &#x02265;300 mg/g or an estimated glomerular filtration rate (eGFR) &#x0003c;60 mL/min/1.73 m&#x000b2;.<xref ref-type="bibr" rid="article-21055.r8">[8]</xref></p>
      </sec>
      <sec id="article-21055.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Chemically enalapril is (<italic toggle="yes">S</italic>)-1-[<italic toggle="yes">N</italic>-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline.&#x000a0;The active form of enalapril is enalaprilat, which inhibits the ACE, thereby reducing the level of angiotensin-II. This action leads to a decrease in total peripheral resistance without an increase in cardiac oxygen demand. Consequently, a decrease in aldosterone and an increase in serum renin levels are observed.<xref ref-type="bibr" rid="article-21055.r9">[9]</xref>&#x000a0;</p>
        <p>Activation of the renin-angiotensin-aldosterone system (RAAS) leads to maladaptive mechanisms,&#x000a0;resulting in cardiac remodeling. ACE inhibitors prevent maladaptive cardiac cell&#x000a0;hypertrophy, facilitate&#x000a0;salt&#x000a0;and water excretion, and increase bradykinin levels by reducing the breakdown, resulting in vasodilation. Comprehensive modulation&#x000a0;of&#x000a0;RAAS by ACE inhibitor enhances&#x000a0;LV function&#x000a0;and cardiac remodeling.<xref ref-type="bibr" rid="article-21055.r10">[10]</xref><xref ref-type="bibr" rid="article-21055.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Enalapril exhibits good oral absorption, with peak concentration achieved in approximately 1 hour.<xref ref-type="bibr" rid="article-21055.r12">[12]</xref></p>
        <p><bold>Distribution:</bold> The volume of distribution for enalapril is 1 to 2.4 L/kg, and according to a recent meta-analysis, it poorly crosses the blood-brain barrier.<xref ref-type="bibr" rid="article-21055.r13">[13]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Organic anion transporting polypeptide-1B1 (OATP1B1) transports enalapril into hepatocytes. Within the hepatocytes, enalapril undergoes metabolism by carboxylesterase 1 (CES1) to enalaprilat, which is its active metabolite.<xref ref-type="bibr" rid="article-21055.r14">[14]</xref><xref ref-type="bibr" rid="article-21055.r15">[15]</xref></p>
        <p><bold>Excretion:</bold> Approximately two-thirds of enalapril is excreted unchanged&#x000a0;in the urine and as enalaprilat. The remaining portion is excreted in the feces via the bile. Renal excretion of enalaprilat involves both glomerular filtration and tubular secretion.<xref ref-type="bibr" rid="article-21055.r16">[16]</xref></p>
      </sec>
      <sec id="article-21055.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>The absorption and metabolism of enalapril remain unaffected by food, making administration independent of food intake. The oral solution is available in a concentration of 1 mg/mL, whereas tablets come in strengths of 2.5 mg, 5 mg, 10 mg, or 20 mg.</p>
        <p>Typical adult dosing regimens range from once to twice daily, depending on the indication. The fixed-dose combination is available as enalapril 5 mg/hydrochlorothiazide 12.5 mg and enalapril 10 mg/hydrochlorothiazide 25 mg.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Hypertension:</bold>&#x000a0;Managing hypertension effectively with enalapril&#x000a0;requires tailored treatment approaches, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients not on diuretics: The recommended initial dosage of enalapril for patients not on diuretics is 5 mg daily, with dosage adjustments based on the patient's blood pressure. The typical dosage range is 10 to 40 mg/d. For patients on daily enalapril&#x000a0;treatment, the antihypertensive effect may diminish near the end of the dosing interval. In such cases, it is advisable to consider twice-daily administration or an increase in the total once-daily dosage.<xref ref-type="bibr" rid="article-21055.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients on concomitant diuretics: If blood pressure remains uncontrolled with enalapril maleate alone, adding a diuretic may be necessary. Patients currently on diuretic therapy may experience symptomatic hypotension following the first dose of enalapril maleate. Notably, it is advisable to discontinue diuretic medication for 2 to 3 days before initiating enalapril treatment. If blood pressure remains uncontrolled with enalapril alone after this period, diuretic therapy can be resumed. If discontinuing the diuretic is not feasible, an initial enalapril&#x000a0;dose of 2.5 mg should be administered to patients under medical supervision. This should be continued for at least 2 hours, with additional monitoring until blood pressure stabilizes for at least another hour.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients on concomitant&#x000a0;potassium supplements, potassium salt substitutes, or potassium-sparing diuretics: Patients coadministering enalapril with all these compounds may experience an elevation in serum potassium levels.</p>
          </list-item>
        </list>
        <p><bold>Heart failure with reduced ejection fraction:&#x000a0;</bold>Enalapril is usually used in combination with diuretics and digitalis for managing symptomatic heart failure. Monitoring patients for at least 2 hours for symptomatic hypotension following the first dose is crucial. The recommended initial dosage of enalapril for heart failure with reduced ejection fraction (HFrEF) is 2.5 mg twice daily. Prescribers are advised to gradually titrate the dosage up to the target range of 10 to 20 mg twice daily, as tolerated by the patient, over several days to weeks.<xref ref-type="bibr" rid="article-21055.r3">[3]</xref>&#x000a0;</p>
        <p>For patients with heart failure whose serum creatinine exceeds 1.6 mg/dL or who have serum sodium levels below 130 mEq/L, enalapril should be initiated at 2.5 mg daily under close medical supervision. The dosage can be escalated to 2.5 mg twice daily, then to 5 mg twice daily, and further increased as necessary, typically every fourth day or longer intervals. Dosage adjustments should be made cautiously, increasing only if excessive hypotension or significant deterioration of renal function is not observed. The maximum daily dosage permitted is 40 mg.</p>
        <p><bold>Asymptomatic left ventricular dysfunction:</bold> In&#x000a0;the clinical trial, patients were initiated on a dosage of 2.5 mg twice daily, with gradual titration to the targeted maximum daily dose of 20 mg, administered in divided daily doses as tolerated.&#x000a0;</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Enalapril should be started at 2.5 mg/d for patients with creatinine clearance less than 30 mL/min and serum creatinine greater than 3 mg/dL. The dosage can be gradually increased, if necessary, until blood pressure is adequately controlled or to a maximum of 40 mg/d.</p>
        <p><bold>Hepatic impairment:</bold> Due to limited available data, enalapril should be used with caution in patients with hepatic impairment.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Enalapril should be discontinued immediately if a patient becomes pregnant, as its use during pregnancy can result in fetal injury and death. Furthermore, there have been reports linking ACE inhibitors to renal dysplasia and oligohydramnios during the second and third trimesters.<xref ref-type="bibr" rid="article-21055.r17">[17]</xref><xref ref-type="bibr" rid="article-21055.r18">[18]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Although enalapril's concentration in breastmilk is low, the amount ingested by the infant is minimal. However, considering the potential adverse reactions in breastfed infants, it is advisable to either discontinue breastfeeding or discontinue enalapril, weighing the risks and benefits carefully.<xref ref-type="bibr" rid="article-21055.r19">[19]</xref></p>
        <p><bold>Pediatric patients:</bold> According to the American Academy of Pediatrics (AAP) guidelines, the recommended initial dosage for patients 1 month or older is 0.08 mg/kg. However, due to insufficient data, enalapril is not recommended for neonates and pediatric patients with a GFR of less than 30 mL/min/1.73m<sup>2</sup>.<xref ref-type="bibr" rid="article-21055.r20">[20]</xref></p>
        <p><bold>Older patients:</bold> Caution is warranted when using enalapril in older patients, as they may be at an increased risk of drug interactions due to polypharmacy.<xref ref-type="bibr" rid="article-21055.r21">[21]</xref></p>
      </sec>
      <sec id="article-21055.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most commonly encountered adverse drug reaction with ACE inhibitors is cough.<xref ref-type="bibr" rid="article-21055.r22">[22]</xref> The cough is characteristically nonproductive and&#x000a0;resolves upon discontinuation of the drug. If dry cough persists after ruling out other potential causes, switching to ARBs is recommended.<xref ref-type="bibr" rid="article-21055.r23">[23]</xref> Other adverse effects associated with enalapril include hypotension, hyperkalemia, angioedema, cholestatic jaundice, and hypersensitivity reactions.</p>
        <p>Vasodilation induced by enalapril, which diminishes the heart's afterload and lowers total peripheral resistance, can lead to hypotension. Initially, patients may experience symptoms such as light-headedness upon standing (orthostatic hypotension), which may progress to fainting spells over time.&#x000a0;</p>
        <p>Aldosterone, the end product of the RAAS, promotes sodium and water reabsorption while facilitating potassium excretion in the kidneys. However, the use of enalapril can interfere with potassium excretion, leading to an accumulation of potassium in the blood, known as hyperkalemia. Hyperkalemia may be asymptomatic if mild or moderate. Chronic hyperkalemia can be entirely asymptomatic, with an electrocardiogram (ECG) showing normal patterns. However, ECG changes indicative of hyperkalemia may include a small or absent P wave, prolonged PR interval, augmented R wave, widened QRS complex, and peaked T waves.<xref ref-type="bibr" rid="article-21055.r24">[24]</xref>&#x000a0;</p>
        <p>Angioedema is a rare but possible adverse effect associated with the use of ACE inhibitors. Notably, its incidence is higher among individuals of African-American descent.<xref ref-type="bibr" rid="article-21055.r25">[25]</xref><xref ref-type="bibr" rid="article-21055.r26">[26]</xref><xref ref-type="bibr" rid="article-21055.r27">[27]</xref> In severe cases, angioedema involving the head and neck regions can pose a risk to the airway. Gastrointestinal involvement may manifest as abdominal pain.<xref ref-type="bibr" rid="article-21055.r28">[28]</xref><xref ref-type="bibr" rid="article-21055.r29">[29]</xref> Furthermore, an important drug interaction to be mindful of is the combination of mammalian target of rapamycin (mTOR) inhibitors and neprilysin inhibitors with ACE inhibitors, as this combination may heighten the risk of angioedema.<xref ref-type="bibr" rid="article-21055.r30">[30]</xref><xref ref-type="bibr" rid="article-21055.r31">[31]</xref></p>
        <p>In rare instances, ACE inhibitors may impact the hepatobiliary system, leading to conditions such as cholestatic jaundice and fulminant hepatic necrosis.<xref ref-type="bibr" rid="article-21055.r32">[32]</xref>&#x000a0;Elevated&#x000a0;hepatic transaminase levels may serve as early indicators, warranting discontinuation of ACE inhibitors in such cases. In addition, clinicians should promptly discontinue the drug if any signs of anaphylaxis or anaphylactoid reactions become evident.</p>
        <p>A recent case report highlights unilateral tongue edema (angioedema) attributed to enalapril.<xref ref-type="bibr" rid="article-21055.r33">[33]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>ACE inhibitors interact with numerous drugs and can cause adverse effects, therapeutic failures, and toxicities. Therefore, it is crucial to consider the following interactions when prescribing enalapril:</p>
        <list list-type="bullet">
          <list-item>
            <p>Drugs that enhance the hypotensive activity of ACE inhibitors include alfuzosin, amifostine, antipsychotic agents, barbiturates, benperidol, brimonidine, dapoxetine, diazoxide, duloxetine, levodopa, loop diuretics, lormetazepam, molsidomine, naftopidil, nicergoline, nitroprusside, obinutuzumab, pholcodine, phosphodiesterase-5 inhibitors, prostacyclin analogs, thiazide and thiazide-like diuretics, and tizanidine.<xref ref-type="bibr" rid="article-21055.r34">[34]</xref><xref ref-type="bibr" rid="article-21055.r35">[35]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drugs that reduce the antihypertensive effect of ACE inhibitors&#x000a0;include amphetamines, aprotinin, brigatinib, bromperidol, dexmethylphenidate, icatibant, lanthanum, methylphenidate, yohimbine, and nonsteroidal anti-inflammatory drugs (NSAIDs).<xref ref-type="bibr" rid="article-21055.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drugs that enhance the adverse effects of ACE inhibitors include&#x000a0;ARBs, dipeptidyl peptidase IV inhibitors, everolimus, racecadotril, ranolazine, salicylates, and sirolimus.<xref ref-type="bibr" rid="article-21055.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drugs that enhance the incidence of hyperkalemia when given concomitantly with ACE inhibitors include aliskiren, drospirenone, eplerenone, heparin, low-molecular-weight heparin, nicorandil, potassium salts, potassium-sparing diuretics, tacrolimus, tolvaptan, and trimethoprim.<xref ref-type="bibr" rid="article-21055.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drugs that ACE inhibitors can enhance the adverse effects of include allopurinol, alteplase, azathioprine, ferric gluconate, ferric hydroxide poly-maltose complex, gelatin (succinylated), gold sodium thiomalate, iron dextran complex, lithium, pregabalin, sacubitril, and sodium phosphate.<xref ref-type="bibr" rid="article-21055.r37">[37]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21055.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Enalapril has a boxed warning for fetal toxicity. Exposure to ACE inhibitors during pregnancy is associated with adverse pregnancy outcomes, including&#x000a0;fetal lung hypoplasia, skeletal malformations, skull hypoplasia,&#x000a0;renal agenesis, and oligohydramnios. ACE inhibitors are also associated with congenital malformations and miscarriages. If&#x000a0;pregnancy is detected, clinicians should promptly discontinue enalapril.<xref ref-type="bibr" rid="article-21055.r38">[38]</xref><xref ref-type="bibr" rid="article-21055.r39">[39]</xref></p>
        <p>
<bold>Contraindications Associated With&#x000a0;Enalapril</bold>
</p>
        <p><bold>Absolute contraindications:</bold> Enalapril is contraindicated in patients with idiopathic angioedema, hereditary angioedema, or a previous history of angioedema associated with ACE inhibitor use.<xref ref-type="bibr" rid="article-21055.r40">[40]</xref>&#x000a0;In addition, the drug is contraindicated in patients with a history of hypersensitivity reactions to ACE inhibitors. Dual blockade of RAAS with enalapril and aliskiren should be avoided, as their concomitant use increases the risk of hyperkalemia, hypotension, and acute renal failure in diabetic patients.&#x000a0;Furthermore, using neprilysin inhibitors, such as sacubitril, with ACE inhibitors heightens the risk of angioedema. Therefore, enalapril should not be administered within 36 hours of transitioning to or from sacubitril/valsartan.<xref ref-type="bibr" rid="article-21055.r30">[30]</xref><xref ref-type="bibr" rid="article-21055.r31">[31]</xref></p>
        <p><bold>Relative contraindications:</bold> Relative contraindications to enalapril use include aortic stenosis, myocardial infarction, stroke, hypertrophic cardiomyopathy, collagen vascular disease such as SLE, bilateral renal artery stenosis, and renal impairment.<xref ref-type="bibr" rid="article-21055.r41">[41]</xref>&#x000a0;Thus, clinicians should exercise caution when prescribing enalapril in these patients, and its use should be avoided if possible</p>
      </sec>
      <sec id="article-21055.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>When administering enalapril to patients with relative contraindications, it is essential to prioritize monitoring vital signs, renal function, and cardiac activity. Clinicians should consider the following tests:</p>
        <list list-type="bullet">
          <list-item>
            <p>The ISH recommends monitoring serum creatinine and eGFR, conducting a dipstick urine test, and obtaining a 12-lead ECG.<xref ref-type="bibr" rid="article-21055.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Serum potassium levels should be regularly monitored.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A complete blood count with a differential should be obtained if agranulocytosis is suspected.<xref ref-type="bibr" rid="article-21055.r42">[42]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (hepatic transaminases) should be monitored in patients with hepatic impairment due to the risk of hepatotoxicity.<xref ref-type="bibr" rid="article-21055.r43">[43]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In heart failure patients, monitoring should include assessing volume status, body weight (simultaneously each day), and clinical signs of congestion and hypoperfusion.<xref ref-type="bibr" rid="article-21055.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For diabetic nephropathy, monitoring the ACR is recommended.<xref ref-type="bibr" rid="article-21055.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21055.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Enalapril toxicity is rare, with hypotension being a major complication. Management typically involves symptomatic treatment, while fluid resuscitation can be utilized to increase intravascular volume. In neonates, peritoneal dialysis can remove enalapril from circulation, while hemodialysis is effective in general cases.</p>
        <p>A recent case report demonstrated the successful use of naloxone for ACE inhibitor overdose, suggesting a potential mechanism involving the endogenous opioid system and accumulation of enkephalins. However, due to the opioid epidemic, concomitant opioid intoxication cannot be excluded. Further research is warranted to explore the use of naloxone in ACE inhibitor poisoning.<xref ref-type="bibr" rid="article-21055.r44">[44]</xref><xref ref-type="bibr" rid="article-21055.r45">[45]</xref></p>
      </sec>
      <sec id="article-21055.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Enalapril is a frequently prescribed medication by clinicians for treating chronic hypertension, heart failure, asymptomatic LV dysfunction, and diabetic nephropathy. Today, approximately 66% of the&#x000a0;older population suffers from hypertension.<xref ref-type="bibr" rid="article-21055.r46">[46]</xref>&#x000a0;According to&#x000a0;The Centers for Disease Control and Prevention (CDC), approximately&#x000a0;6.2 million&#x000a0;adults in the&#x000a0;United States were diagnosed with heart failure in 2020, with ACE inhibitors commonly used in treatment.<xref ref-type="bibr" rid="article-21055.r47">[47]</xref>&#x000a0;</p>
        <p>Healthcare providers should be mindful during routine checkups that patients using ACE inhibitors and those aged 70 or older are at a higher risk of developing hyperkalemia.<xref ref-type="bibr" rid="article-21055.r48">[48]</xref>&#x000a0;In contrast,&#x000a0;patients younger than 70 and on ACE inhibitors typically develop only mild-to-moderate hyperkalemia. Patients taking ACE inhibitors with blood urea nitrogen (BUN) higher than 8.9 mmol/L are at an increased risk of developing hyperkalemia.<xref ref-type="bibr" rid="article-21055.r48">[48]</xref>&#x000a0;As severe hyperkalemia can precipitate life-threatening complications, healthcare providers should provide adequate counseling to such patients about these risks.&#x000a0;Chronic hyperkalemia can manifest as entirely asymptomatic, with no discernible ECG changes. Thus, relying solely on ECG for diagnosing hyperkalemia may be insufficient. Timely diagnosis of severe hyperkalemia is imperative, as it can lead to life-threatening complications such as cardiac arrest.<xref ref-type="bibr" rid="article-21055.r49">[49]</xref>&#x000a0;</p>
        <p>Although enalapril is a widely used and generally well-tolerated medication, its proper utilization and management necessitate the collaboration of an interprofessional healthcare team comprising clinicians, specialists, nurses, and pharmacists. This collaboration facilitates shared decision-making and ensures patient safety. Participating clinicians&#x000a0;can&#x000a0;deliver optimal care to patients with hypertension and related conditions through effective communication and essential information obtained from this activity.</p>
      </sec>
      <sec id="article-21055.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21055&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21055">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21055/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21055">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21055.s11">
        <title>References</title>
        <ref id="article-21055.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alsheikh-Ali</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rand</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Konstam</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Homoud</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Estes</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Al-Ahmad</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction.</article-title>
            <source>Am Heart J</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>147</volume>
            <issue>6</issue>
            <fpage>1061</fpage>
            <page-range>1061-5</page-range>
            <pub-id pub-id-type="pmid">15199356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Mansukhani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Heart Failure: A Class Review of Pharmacotherapy.</article-title>
            <source>P T</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>7</issue>
            <fpage>464</fpage>
            <page-range>464-472</page-range>
            <pub-id pub-id-type="pmid">28674474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>79</volume>
            <issue>17</issue>
            <fpage>e263</fpage>
            <page-range>e263-e421</page-range>
            <pub-id pub-id-type="pmid">35379503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charchar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Prabhakaran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schlaich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stergiou</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wainford</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schutte</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>2020 International Society of Hypertension Global Hypertension Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1334</fpage>
            <page-range>1334-1357</page-range>
            <pub-id pub-id-type="pmid">32370572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reed</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Sueta</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Stage B: what is the evidence for treatment of asymptomatic left ventricular dysfunction?</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2015</year>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-22</page-range>
            <pub-id pub-id-type="pmid">24251458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chatellier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Leblanc</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guyene</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Menard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Passa</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.</article-title>
            <source>BMJ</source>
            <year>1988</year>
            <month>Oct</month>
            <day>29</day>
            <volume>297</volume>
            <issue>6656</issue>
            <fpage>1092</fpage>
            <page-range>1092-5</page-range>
            <pub-id pub-id-type="pmid">2848604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Boer</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sadusky</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tuttle</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Neumiller</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).</article-title>
            <source>Diabetes Care</source>
            <year>2022</year>
            <month>Dec</month>
            <day>01</day>
            <volume>45</volume>
            <issue>12</issue>
            <fpage>3075</fpage>
            <page-range>3075-3090</page-range>
            <pub-id pub-id-type="pmid">36189689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Todd</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.</article-title>
            <source>Drugs</source>
            <year>1992</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>346</fpage>
            <page-range>346-81</page-range>
            <pub-id pub-id-type="pmid">1374319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshiyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Omura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iwao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yoshikawa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice.</article-title>
            <source>Heart</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>91</volume>
            <issue>8</issue>
            <fpage>1080</fpage>
            <page-range>1080-5</page-range>
            <pub-id pub-id-type="pmid">16020603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000fc;sing</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering.</article-title>
            <source>Ther Adv Cardiovasc Dis</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>151</fpage>
            <page-range>151-61</page-range>
            <pub-id pub-id-type="pmid">27122491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Portol&#x000e9;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terleira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Arenillas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caturla</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Filipe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers.</article-title>
            <source>Curr Ther Res Clin Exp</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-46</page-range>
            <pub-id pub-id-type="pmid">24936102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manly</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rajan</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Hudak</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hasebe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Laurin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carmichael</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Nation</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis.</article-title>
            <source>Hypertension</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>629</fpage>
            <page-range>629-643</page-range>
            <pub-id pub-id-type="pmid">34148364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stage</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>J&#x000fc;rgens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guski</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bjerre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferrero-Miliani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lyauk</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Dalhoff</surname>
                <given-names>K</given-names>
              </name>
              <collab>INDICES Consortium (for members of this consortium-see Supplementum)</collab>
            </person-group>
            <article-title>The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>121</volume>
            <issue>6</issue>
            <fpage>487</fpage>
            <page-range>487-492</page-range>
            <pub-id pub-id-type="pmid">28639420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomsen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Linnet</surname>
                <given-names>K</given-names>
              </name>
              <collab>INDICES Consortium</collab>
            </person-group>
            <article-title>In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>126</fpage>
            <page-range>126-33</page-range>
            <pub-id pub-id-type="pmid">24141856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smeets</surname>
                <given-names>NJL</given-names>
              </name>
              <name>
                <surname>Litjens</surname>
                <given-names>CHC</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>JJMW</given-names>
              </name>
              <name>
                <surname>van Hove</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van den Broek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Russel</surname>
                <given-names>FGM</given-names>
              </name>
              <name>
                <surname>Koenderink</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>de Wildt</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Completing the Enalaprilat Excretion Pathway-Renal Handling by the Proximal Tubule.</article-title>
            <source>Pharmaceutics</source>
            <year>2020</year>
            <month>Sep</month>
            <day>30</day>
            <volume>12</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">33007874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <page-range>e26-e50</page-range>
            <pub-id pub-id-type="pmid">30575676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buawangpong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Teekachunhatean</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koonrungsesomboon</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>e00644</fpage>
            <pub-id pub-id-type="pmid">32815286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Enalapril</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>8</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">29999642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flynn</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kaelber</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Baker-Smith</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Blowey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Dionne</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Falkner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leu</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Rea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simasek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thaker</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Urbina</surname>
                <given-names>EM</given-names>
              </name>
              <collab>SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN</collab>
            </person-group>
            <article-title>Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>140</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28827377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ju&#x000e1;rez-Cedillo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Martinez-Hern&#x000e1;ndez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Constantino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia-Cruz</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Avalos-Mejia</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Hurtado</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Islas Perez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hansten</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Clinical Weighting of Drug-Drug Interactions in Hospitalized Elderly.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>298</fpage>
            <page-range>298-305</page-range>
            <pub-id pub-id-type="pmid">26432499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben Salem</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Badreddine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fathallah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Slim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hmouda</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced hyperkalemia.</article-title>
            <source>Drug Saf</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>677</fpage>
            <page-range>677-92</page-range>
            <pub-id pub-id-type="pmid">25047526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jadhav</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Singhai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sadhanandham</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>ACEI-induced cough: A review of current evidence and its practical implications for optimal CV risk reduction.</article-title>
            <source>Indian Heart J</source>
            <year>2020</year>
            <season>Sep-Oct</season>
            <volume>72</volume>
            <issue>5</issue>
            <fpage>345</fpage>
            <page-range>345-350</page-range>
            <pub-id pub-id-type="pmid">33189192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Simon</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperkalemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">29261936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibbs</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Beevers</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Angioedema due to ACE inhibitors: increased risk in patients of African origin.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>861</fpage>
            <page-range>861-5</page-range>
            <pub-id pub-id-type="pmid">10594491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Snowden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-13</page-range>
            <pub-id pub-id-type="pmid">8689816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kostis</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Rusnak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casale</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Incidence and characteristics of angioedema associated with enalapril.</article-title>
            <source>Arch Intern Med</source>
            <year>2005</year>
            <month>Jul</month>
            <day>25</day>
            <volume>165</volume>
            <issue>14</issue>
            <fpage>1637</fpage>
            <page-range>1637-42</page-range>
            <pub-id pub-id-type="pmid">16043683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitor angioedema of the intestine: a case report and review of the literature.</article-title>
            <source>Am J Med Sci</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>324</volume>
            <issue>2</issue>
            <fpage>106</fpage>
            <page-range>106-8</page-range>
            <pub-id pub-id-type="pmid">12186104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oudit</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Girgrah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Allard</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>ACE inhibitor-induced angioedema of the intestine: Case report, incidence, pathophysiology, diagnosis and management.</article-title>
            <source>Can J Gastroenterol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>827</fpage>
            <page-range>827-32</page-range>
            <pub-id pub-id-type="pmid">11773949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duerr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glander</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Diekmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dragun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Neumayer</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>703</fpage>
            <page-range>703-8</page-range>
            <pub-id pub-id-type="pmid">20093343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charmillon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deibener</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaminsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Louis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Angioedema induced by angiotensin converting enzyme inhibitors, potentiated by m-TOR inhibitors: successful treatment with icatibant.</article-title>
            <source>Intensive Care Med</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>893</fpage>
            <page-range>893-4</page-range>
            <pub-id pub-id-type="pmid">24737261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Todd</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Levison</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Farthing</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Enalapril-related cholestatic jaundice.</article-title>
            <source>J R Soc Med</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>271</fpage>
            <page-range>271-2</page-range>
            <pub-id pub-id-type="pmid">2342045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gil Braga</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cravo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neves</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mendon&#x000e7;a</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A Rare Case of Unilateral Tongue Edema with Angiotensin Converting Enzyme Inhibitors.</article-title>
            <source>Acta Med Port</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>35</volume>
            <issue>7-8</issue>
            <fpage>588</fpage>
            <page-range>588-590</page-range>
            <pub-id pub-id-type="pmid">35612179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kao</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Hypotension due to interaction between lisinopril and tizanidine.</article-title>
            <source>Ann Pharmacother</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>1840</fpage>
            <page-range>1840-3</page-range>
            <pub-id pub-id-type="pmid">15383642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Tobias</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.</article-title>
            <source>J Child Neurol</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>818</fpage>
            <page-range>818-9</page-range>
            <pub-id pub-id-type="pmid">11198499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burdese</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guarena</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Consiglio</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mezza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soragna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Segoloni</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Piccoli</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Sirolimus and ACE-inhibitors: a note of caution.</article-title>
            <source>Transplantation</source>
            <year>2005</year>
            <month>Jan</month>
            <day>27</day>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>251</fpage>
            <page-range>251-2</page-range>
            <pub-id pub-id-type="pmid">15665781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stack</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Alterman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing.</article-title>
            <source>Hum Pathol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>675</fpage>
            <page-range>675-84</page-range>
            <pub-id pub-id-type="pmid">15188133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levitt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Amsalem</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Reversible Fetal Renal Impairment following Angiotensin Receptor Blocking Treatment during Third Trimester of Pregnancy: Case Report and Review of the Literature.</article-title>
            <source>Case Rep Obstet Gynecol</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>2382031</fpage>
            <pub-id pub-id-type="pmid">27672462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shrim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kingdom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hamoudi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy. Fetal toxicity could be reversible.</article-title>
            <source>Can Fam Physician</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>10</issue>
            <fpage>1335</fpage>
            <page-range>1335-7</page-range>
            <pub-id pub-id-type="pmid">16250418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kostis</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kostis</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>ACE Inhibitor-Induced Angioedema: a Review.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2018</year>
            <month>Jun</month>
            <day>08</day>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>55</fpage>
            <pub-id pub-id-type="pmid">29884969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khosla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benatar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Elbzour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vidyarthi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lubell</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Safety of angiotensin-converting enzyme inhibitors in patients with bilateral renal artery stenosis following successful renal artery stent revascularization.</article-title>
            <source>Am J Ther</source>
            <year>2006</year>
            <season>Jul-Aug</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>306</fpage>
            <page-range>306-8</page-range>
            <pub-id pub-id-type="pmid">16858164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lorenzo-Villalba</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alonso-Ortiz</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Maouche</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zulfiqar</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Andr&#x000e8;s</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients.</article-title>
            <source>J Clin Med</source>
            <year>2020</year>
            <month>Jun</month>
            <day>10</day>
            <volume>9</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">32531979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r43">
          <label>43</label>
          <element-citation publication-type="book">
            <chapter-title>Enalapril</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>2</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">31643271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trivedi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Glezerson</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doufl&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Naloxone as an antidote for angiotensin converting enzyme inhibitor poisoning: a case report.</article-title>
            <source>Can J Anaesth</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>10</issue>
            <fpage>1442</fpage>
            <page-range>1442-1443</page-range>
            <pub-id pub-id-type="pmid">32342351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samanta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Samanta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baronia</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ramipril poisoning rescued by naloxone and terlipressin.</article-title>
            <source>Saudi J Anaesth</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>311</fpage>
            <page-range>311-2</page-range>
            <pub-id pub-id-type="pmid">24843362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>QT</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Managing hypertension in the elderly: a common chronic disease with increasing age.</article-title>
            <source>Am Health Drug Benefits</source>
            <year>2012</year>
            <month>May</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>146</fpage>
            <page-range>146-53</page-range>
            <pub-id pub-id-type="pmid">24991317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Bittencourt</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Callaway</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delling</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Djousse</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Elkind</surname>
                <given-names>MSV</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Fornage</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kissela</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Knutson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Lichtman</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Longenecker</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Loop</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lutsey</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Mussolino</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Perak</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rosamond</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>UKA</given-names>
              </name>
              <name>
                <surname>Satou</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Shay</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Spartano</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Stokes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tirschwell</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>VanWagner</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Tsao</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee</collab>
            </person-group>
            <article-title>Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2020</year>
            <month>Mar</month>
            <day>03</day>
            <volume>141</volume>
            <issue>9</issue>
            <fpage>e139</fpage>
            <page-range>e139-e596</page-range>
            <pub-id pub-id-type="pmid">31992061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reardon</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Macpherson</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?</article-title>
            <source>Arch Intern Med</source>
            <year>1998</year>
            <month>Jan</month>
            <day>12</day>
            <volume>158</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-32</page-range>
            <pub-id pub-id-type="pmid">9437375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21055.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raebel</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.</article-title>
            <source>Cardiovasc Ther</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>e156</fpage>
            <page-range>e156-66</page-range>
            <pub-id pub-id-type="pmid">21883995</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
